State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, China.
West China School of Medicine, West China Hospital, Sichuan University, Chengdu, 610041, PR China.
Sci Rep. 2018 Feb 14;8(1):3044. doi: 10.1038/s41598-018-21093-7.
This study was to evaluate the prognostic value of pretreatment inflammatory indexes including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), and systemic immune-inflammation index (SII) in colorectal cancer (CRC) patients receiving neoadjuvant chemoradiotherapy (CRT). We enrolled 98 eligible CRC patients and divided them into high or low NLR, PLR, LMR, and SII groups according to their median index value, respectively. Univariate and multivariate analysis were performed to identify the potential predictors of progression-free survival (PFS) and overall survival (OS). In the univariate analysis, ECOG performance status, distant metastasis, NLR, PLR, LMR, and SII were found to be significantly associated with PFS and OS. In the multivariate analysis, ECOG performance status, distant metastasis, and NLR were identified to be independent predictors of PFS (HR 2.487, p = 0.012; HR 2.422, p = 0.042; HR 2.243, p = 0.034, respectively), and OS (HR 2.237, p = 0.018; HR 2.757, p = 0.020; HR 2.336, p = 0.017, respectively). The results of our study revealed that ECOG performance status, distant metastasis and NLR were independent prognostic factors of PFS and OS in CRC patients receiving neoadjuvant CRT.
本研究旨在评估包括中性粒细胞与淋巴细胞比值（NLR）、血小板与淋巴细胞比值（PLR）、淋巴细胞与单核细胞比值（LMR）和全身免疫炎症指数（SII）在内的预处理炎症指标在接受新辅助放化疗（CRT）的结直肠癌（CRC）患者中的预后价值。我们纳入了 98 例符合条件的 CRC 患者，并根据中位数指数值将他们分为高或低 NLR、PLR、LMR 和 SII 组。进行单因素和多因素分析以确定无进展生存期（PFS）和总生存期（OS）的潜在预测因素。在单因素分析中，ECOG 表现状态、远处转移、NLR、PLR、LMR 和 SII 与 PFS 和 OS 显著相关。在多因素分析中，ECOG 表现状态、远处转移和 NLR 被确定为 PFS（HR 2.487，p=0.012；HR 2.422，p=0.042；HR 2.243，p=0.034）和 OS（HR 2.237，p=0.018；HR 2.757，p=0.020；HR 2.336，p=0.017）的独立预测因素。我们的研究结果表明，ECOG 表现状态、远处转移和 NLR 是接受新辅助 CRT 的 CRC 患者 PFS 和 OS 的独立预后因素。
